In this interview, Christopher Fox, MBChB(Hons), MRCP, FRCPath, of Nottingham University Hospitals NHS Trust, Nottingham, UK, provides an overview of…
Browsing: Chronic Lymphocytic Leukemia
Relapse and failure of ibrutinib and idelalisib regimens in chronic lymphocytic leukaemia (CLL) is becoming an increasingly common. Here, Christopher…
Current diagnostic techniques for chronic lymphocytic leukemia (CLL), which include Sanger sequencing and fluorescent in-situ hybridization, can be complex and…
Ana Limon Carrera, Takeda Oncology, talks about Working in Leukemias, Will Enter into Solid Tumors | Molecule TAK-931 is the…
Ana Limon Carrera, Takeda Oncology, talks about Studying Tumors in Pancreatic & Colorectal Patients | Hope to Confirm Safety &…
Michelle Dawson, MD, AstraZeneca, talks about Chemo-free Regimens for Patients Moxetumomab delivers different experience at Annual Meeting 2018.
Michelle Dawson, MD, AstraZeneca, talks AstraZeneca is Relatively New Six Agents in Phase 1 & another Six in Phase 2…
Rafael G Amado, MD, Adaptimmune, LLC, explains Updates of Positive CAR-T Studies & Approval Speaks to the power and potential…
Michelle Dawson, MD, AstraZeneca, talks about FDA Accepted Moxetumomab BLA Studies looking for toxicities and developments at Annual Meeting 2018.
Michelle Dawson, MD, AstraZeneca, talks about Adverse Effects for Moxetumomab Pasudotox Mild percentages of headache, nausea, HUS, CLS at Annual…
Michelle Dawson, MD, AstraZeneca, talks about Moxetumomab Pasudotox is Unique Immunotoxin Fused pseudomonas exotoxin with antibody variable at Annual Meeting…
Michelle Dawson, MD, AstraZeneca, talks about 75% Overall Response from Moxetumomab 41% of patients had complete response at Annual Meeting…
Michelle Dawson, MD, AstraZeneca, talks about Moxetumomab Pasudotox Pivotal in relapse refractory hairy cell leukemia at Annual Meeting 2018.
Paul G. Richardson, MD, explains Selinexor is a Novel Mechanism of Action Venetoclax Serves a Challenging Population at Imedex Great…
Paul G. Richardson, MD, explains Role of Venetoclax in Plasma Cell Leukemia Excellent partner drug with non-overlapping toxicities at Imedex…
Paul G. Richardson, MD, explains Powerful new IMiDs, CC-220 & CC-92480 Importance of Small Molecules in advanced trials at Imedex…
Paul G. Richardson, MD, explains Melflufen is a Modified Derivative of Melphalan Peptidase-avid and a targeted form of chemotherapy at…
Paul G. Richardson, MD, explains Selinexor is an Inhibitor of Nuclear Export Proteins Synergy with Bortezeomib on anti-myeloma activity at…
Paul G. Richardson, MD, explains Venetoclax Shown Great Results with Bortezomib It targets 11;14, oral, well-tolerated at Imedex Great Debates…
Richard R. Furman, MD, explains how Prognostics are difficult in the MBL population Del17P & NOTCH1 are relevant for time…
Amer M Zeidan, MBBS, explains Enasidenib, an IDH2 Inhibitor based on Phase 1 Trial High-Response rate in patients with IDH2…
Jose F. Leis, MD, PhD, explains the Treatment of CLL & Richter’s Transformations High Risk Patients will progress their disease…
Dramatic progress has been made in our understanding of the clinical, biological and molecular heterogeneity of chronic lymphocytic leukemia (CLL).…